What is Quince Therapeutics, Inc. (QNCX) stock price today?

Quince Therapeutics, Inc. (QNCX) currently trades at $1.31 per share. The stock has a market capitalization of $20.05M and a P/E ratio of —x.

Is QNCX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Quince Therapeutics, Inc. has a Smart Value Score of 16/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -5.46.

Is Quince Therapeutics, Inc. financially healthy?

Quince Therapeutics, Inc.'s Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -5.46 places it in the distress.

QNCX

Quince Therapeutics, Inc.

NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY

$1.31

+6.50% today

Updated 2026-04-30

Market cap

$20.05M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-16.80

Dividend yield

—

52W range

$1 – $46

Volume

63.6M

Market cap

$20.05M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-16.80

Dividend yield

—

52W range

$1 – $46

Volume

63.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

2.5

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-5.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$5.00

+281.68%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy4 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -5.46 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-10.62M

- Debt/equity 16.99x — high leverage

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-51.66M	$-31.39M	$-56.83M	$-83.98M	$-39.46M
EPS	—	—	—	—	$-16.80
Free cash flow	$-44.17M	$-18.45M	$-32.16M	$-41.78M	$-10.62M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
QNCX	$20.05M	16	4.3	3.0	5.0	2.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Quince Therapeutics, Inc. trades at $1.31. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -5.46, it sits in the distress.

Frequently asked questions

What is Quince Therapeutics, Inc.'s stock price?

Quince Therapeutics, Inc. (QNCX) trades at $1.31.

Is Quince Therapeutics, Inc. overvalued?

Smart Value Score 16/100 (Grade F, Strong Sell).

What is the price target of Quince Therapeutics, Inc. (QNCX)?

The analyst target price is $5.00, representing +281.7% upside from the current price of $1.31.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-5.46 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-247.80%

Beta1.33

50D MA$1.20

200D MA$15.90

Shares out0.02B

Float0.02B

Short ratio—

Avg volume63.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

QNCX vs LLY →QNCX vs JNJ →QNCX vs ABBV →Stock screener →